Status:
UNKNOWN
The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.
Lead Sponsor:
Sheppard Pratt Health System
Collaborating Sponsors:
COMPASS Pathways
Conditions:
Treatment Resistant Depression
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive ...
Eligibility Criteria
Inclusion
- Diagnosis of Type 2 Bipolar Disorder (BP-II) Depression
Exclusion
- Comorbidities
Key Trial Info
Start Date :
March 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 15 2023
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04433845
Start Date
March 1 2021
End Date
April 15 2023
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheppard Pratt
Baltimore, Maryland, United States, 21204